A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
Most of the time, uterine cold is caused by too much cold energy in the body.
Nasopharyngeal cancer is a very complex disease that causes abnormal symptoms in the ears and nose, which can seriously affect the health and living conditions of patients with nasopharyngeal cancer.
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have now identified a new treatment that promises to help cancer patients with bone marrow transplants manage side effects better than current standard therapies, making the treatment more effective and safer.
According to researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, a new treatment that helps the immune system kill multiple myeloma cancer cells has benefited up to 73% of patients in 2 clinical trials!
Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.
The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.
Anemia is a very common problem among women. Anemia makes people less resistant and depressed, and serious anemia can also endanger the health of the body, so when the situation of anemia occurs, it should be promptly adjusted. The actual fact is that you will be able to get a lot more than just a few of the most popular and popular items.
The trial is testing the effectiveness of two chemotherapy drugs, oxaliplatin and gemcitabine, in combination with radiotherapy, an approach that has been used to treat other aggressive tumours
Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!
